Related Experiment Video
Updated: Jul 28, 2025

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
Published on: April 7, 2015
An unusual case of checkpoint-inhibitor-induced pleuropericarditis
Zoilo K Suarez1, Ana C Finke2, Emilio Hospedales1
1Internal Medicine Department, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, USA.
Introduction:
Pembrolizumab is an immune checkpoint inhibitor that promotes effector T-cell functions on malignant cells by binding to programmed cell death protein 1 (PD-1). Pembrolizumab is well tolerated in most cases with an adverse event profile consisting mainly of pruritus, fatigue, and anorexia. Cardiotoxicity comprises 1% of the total adverse events.
Case Report:
We present a case of a 64-year-old female with non-small cell lung cancer (NSCLC) who developed pleuropericarditis following pembrolizumab therapy.
Management & Outcome:
The patient was successfully managed with colchicine, furosemide, and timely initiation of methylprednisolone with the improvement of her symptoms. The decision to discontinue pembrolizumab was made, and six months after this intervention, the patient has remained asymptomatic.
Discussion:
Clinicians should recognize these potential immune-mediated adverse effects to provide effective and timely management and optimize patient care.
More Related Videos
Related Concept Videos
Pericarditis II: Clinical Features and Diagnostic Tests
Pericarditis I: Introduction
Pericarditis IV: Nursing Management
Pericarditis III: Medical Management
Endocarditis IV: Nursing Management
Myocarditis II: Clinical Features and Diagnostic Tests

